Life Science Investing BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
Life Science Investing BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
Life Science Investing BioRestorative Awarded Notice of Allowance for Japanese Patent - Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
Life Science Investing BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
Life Science Investing BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
Life Science Investing BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
Homerun Resources Inc. Receives Conditional Approval from the TSXV for $6 Million Financing with Institutional Investor
Silver Dollar Samples Up to 2,753 g/t AgEq in Underground Sampling Campaign at its La Joya Silver Project
